Seasonal allergic rhinitis research hub

2 indexed studies · 0 currently recruiting

authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, single dose, two-treatment, four period, two-sequence, crossover, fully replicate, bioequivalence study comparing Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablet USP 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fasting conditions.
This study compares a generic allergy tablet with a branded medicine called Allegra-D 24 HR. Both tablets treat hay fever and blocked noses. Researchers want to confirm that healthy adult bodies absorb the generic tablet in the exact same way as the branded version when taken on an empty stomach.
Romania
authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, balanced, randomized, single dose, two-treatment, two period, two-sequence, crossover, bioequivalence study comparing Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablet 180 mg/240 mg, Manufactured by: Sun Pharmaceutical Industries Limited, India with Allegra-D® 24 HR (Fexofenadine HCl and Pseudoephedrine HCl Extended Release Tablets 180 mg + 240 mg) tablets, Distributed by: Chattem Inc., a Sanofi Company Chattanooga, TN 37409-0219, USA, in healthy, adult, human participants under fed conditions.
This study tests whether a new generic allergy tablet works the same way in the body as the brand-name medicine, Allegra-D. Both contain fexofenadine and pseudoephedrine to treat hay fever. Healthy adult volunteers will take a single dose of each tablet after eating a meal to compare blood levels.
Romania